The Role of Levator Ani Muscle Reconstruction Technology in Urinary Incontinence Recovery
The Role of Levator Ani Muscle Reconstruction Technology in Urinary Incontinence Recovery After Robot Assisted Radical Prostatectomy: a Randomized Controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study is a single center, single blind, prospective randomized controlled trial. Collect baseline data from enrolled patients Materials were randomly divided into experimental group A (lateral reconstruction group), experimental group B (posterior reconstruction group), and control group (non reconstruction group) in a 1:1:1 ratio using a computer-generated random number sequence.
In the control group (non reconstruction group), no lateral or posterior reconstruction was performed after RARP surgery.
In experimental group A (lateral reconstruction group), lateral reconstruction was performed after RARP surgery, in which the levator ani muscle was sutured to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.
In experimental group B (post reconstruction group), post reconstruction was performed after RARP surgery.
This study used blinding on patients to avoid subjective factors affecting the results of whether reconstruction was performed or not.
Preoperative collection of baseline data from patients includes age, BMI, history of abdominal surgery, most recent PSA, PI-RADS score, prostate volume, prostate puncture related data (histological type, number of positive needles/puncture needles, Gleason score, maximum tumor proportion), PSMA PET-CT results, neoadjuvant therapy regimen, International Advisory Committee on Urinary Incontinence Questionnaire Brief (ICIQ-SF) score, International Index of Erectile Function (IIEF-5) score, International Prostate Symptom Score (IPSS) score, etc.
Collect postoperative patient surgical data (including ASA score, surgical duration, intraoperative blood loss, etc.), hospitalization data (including hospitalization duration, hospitalization costs, etc.), and pathological data (including lesion diameter, histological type, Gleason score, pathological staging, positive surgical margin, invasion of capsule, invasion of seminal vesicle and adjacent tissues, etc.).
Follow up visits were conducted on patients at 1, 3, 6, 9, and 12 months postoperatively, and relevant clinical data were collected, including the number of urine pads used per day during follow-up, ICIQ-SF score, 24-hour urine leakage (accurately measured by purchasing an electronic scale for patients), perioperative and postoperative complications, IIEF-5 score, PSA, and urinary incontinence quality of life questionnaire (I-QOL) score, in order to evaluate the improvement effect of lateral reconstruction on urinary control and quality of life, as well as the impact on complication incidence, erectile function, and tumor control. The differences in the effects of lateral reconstruction and posterior reconstruction on urinary control recovery and quality of life improvement were compared.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kan Gong, MD
- Phone Number: (86)-010-83572075
- Email: kan.gong@bjmu.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Contact:
- Kan Gong
- Phone Number: (86)-010-83572057
- Email: kan.gong@bjmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with prostate cancer and preoperative clinical stage of cT2~T3aN0M0
- Complies with the indications for RARP surgery
Exclusion Criteria:
- History of urinary incontinence or urethral stricture
- Previous prostate related surgical treatment
- Contraindications for RARP surgery
- The patient or their family members refuse to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: lateral reconstruction group
After RARP surgery, lateral reconstruction is performed
|
In lateral reconstruction group, lateral reconstruction is performed by suturing the levator ani muscle to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.
|
|
Experimental: posterior reconstruction group
After RARP surgery, posterior reconstruction is performed
|
In posterior group, prior to completion of the operation, the posterior fibrous tissues of the sphincter are joined to the residual Denonvilliers fascia on the posterior bladder wall 1-2 cm cephalad and dorsally to the new bladder neck.
|
|
No Intervention: control group
No lateral or posterior reconstruction is performed after RARP surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recovery rate of urinary incontinence
Time Frame: 1,3,6,9,12 months after operation
|
Urinary incontinence recovery is defined as using 0 urinary pads per day
|
1,3,6,9,12 months after operation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The International Consultation on Incontinence Questionnaire Short-form(ICIQ-SF) Score
Time Frame: 1,3,6,9,12 months after operation
|
ICIQ-SF is a questionnaire used to evaluate urinary incontinence and assess the recovery of postoperative urinary incontinence in patients.
The range of scores is from 0 to 21, with higher scores indicating more severe urinary incontinence.
|
1,3,6,9,12 months after operation
|
|
Incontinence Quality of Life Questionnaire(I-QOL) Score
Time Frame: 1,3,6,9,12 months after operation
|
I-QoL is a questionnaire used to evaluate the quality of life of patients with urinary incontinence after surgery.
The range of scores is from 0 to 100, with higher scores indicating higher quality of life.
|
1,3,6,9,12 months after operation
|
|
Perioperative and postoperative complications
Time Frame: 1,3,6,9,12 months after operation
|
Collect perioperative and postoperative complications such as bleeding and pain to compare the differences between two reconstruction methods and non reconstruction methods.
|
1,3,6,9,12 months after operation
|
|
Prostate-specific antigen
Time Frame: 1,3,6,9,12 months after operation
|
Biochemical recurrence is defined as two consecutive postoperative PSA levels above 0.2 ng/ml with an upward trend
|
1,3,6,9,12 months after operation
|
|
Duration of operation
Time Frame: immediately after operation
|
The purpose of collecting surgical duration is to compare whether there are differences between two reconstruction techniques and no reconstruction.
|
immediately after operation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kan Gong, Peking University First Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Genital Neoplasms, Male
- Prostatic Diseases
- Urination Disorders
- Elimination Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Urinary Incontinence
- Enuresis
Other Study ID Numbers
Other Study ID Numbers
- chfcj2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.